SAFETY DATA SHEETS

This SDS packet was issued with item:

078043727

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078043420 078043438 078043446 078043453 078043461 078043479 078043537 078043545 078043677 078043685 078043693 078043701 078043719 078043735 078043743 078543708 078543716



MATERIAL SAFETY DATA SHEET

SOLOXINE[®] (Levothyroxine Sodium) Tablets Product Codes: 830100, 830250, 831100, 831250, 832100, 832250, 833100, 833250, 834100, 834250, 835100, 835250, 836100, 836250, 837100, 837250, 838100, and 838250

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATIONS AND OF THE COMPANY UNDERTAKING

Product Name SOLOXINE® (Levothyroxine Sodium) Tablets

Product Description Thyroid replacement for dogs

Manufacturer/Supplier Virbac AH, Inc.

Address P.O. Box 162059

Fort Worth, Texas 76161

Phone Number (800) 338-3659 **Chemtrec Number (24 hour)** (800) 424-9300

Other Emergency Numbers: Poison Control Center: 1-800-222-1222

MSDS Revision Date: October 17, 2011 Supersedes MSDS Dated: March 19. 2009

Material Safety Data Sheet in compliance with OSHA's Hazcom Standard (29 CFR 1910.1200)

2. HAZARDS IDENTIFICATION

Emergency Overview CAUTION!

May cause adverse heart and central nervous system effects.

Keep out of reach of children.

Routes of Entry

Ingestion

Carcinogenic Status

Not considered carcinogenic by NTP, IARC, and OSHA.

Target Organs

Heart - Central Nervous System

Health Effects - Eyes

Not an expected route of entry during normal handling and use.

Health Effects - Skin

Contact with skin is not expected to cause adverse effects.

Health Effects - Ingestion

Ingestion of this material may cause gastrointestinal effects such as nausea and vomiting, and adverse heart and central nervous system effects.

Health Effects – Inhalation

Not an expected route of entry during normal handling and use.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Component NameCAS NumberConcentrationLevothyroxine Sodium25416-65-3See below

Available in 0.1mg, 0.2mg, 0.3mg, 0.4mg, 0.5mg, 0.6mg, 0.7mg, 0.8mg and 1.0mg of levothyroxine sodium per tablet

Revision Date: October 17, 2011 Page 1 of 5



Material Safety Data Sheet SOLOXINE® (Levothyroxine Sodium) Tablets Product Codes: 830100, 830250, 831100, 831250, 832100, 832250, 833100,

Product Codes: 830100, 830250, 831100, 831250, 832100, 832250, 833100, 833250, 834100, 834250, 835100, 835250, 836100, 836250, 837100, 837250, 838100, and 838250

4. FIRST AID MEASURES

Eves

Not an expected route of entry. If tablet contacts eye, flush thoroughly with water. If pain or irritation persist contact a physician.

Skin

Wash skin thoroughly with soap and water. Obtain medical attention if redness or soreness persists.

Ingestion

Contact a physician immediately if ingested. Physician may call a poison control center for advice concerning human ingestion.

Inhalation

Not applicable

Advice to Physicians

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

5. FIRE - FIGHTING MEASURES

Extinguishing Media

Use extinguishing media appropriate for surrounding materials.

Unusual Fire and Explosion Hazards

Can release hazardous vapors during a fire.

Protective Equipment for Fire-Fighting

Wear full protective clothing and self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Sweep and dispose of small amounts in trash. Large amounts should be disposed of in a sanitary landfill.

7. HANDLING AND STORAGE

Store in original container at temperatures between 59°F and 86°F (15°C - 30°C). Keep out of sunlight. Keep away from children. Wash hands after dispensing to dog before eating, drinking or smoking.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Occupational Exposure Standards

Exposure limits are listed below, if they exist.

Levothyroxine Sodium

None established

Engineering Control Measures

No specific measures necessary. Good general room ventilation is expected to be adequate to control airborne levels.

Respiratory Protection

Not required under normal conditions of use.

Hand Protection

Not required under normal conditions of use. Workers should wash hands before eating, drinking or smoking.

Eye Protection

Not required under normal conditions of use.

Revision Date: October 17, 2011 Page 2 of 5



Material Safety Data Sheet SOLOXINE® (Levothyroxine Sodium) Tablets

Product Codes: 830100, 830250, 831100, 831250, 832100, 832250, 833100, 833250, 834100, 834250, 835100, 835250, 836100, 836250, 837100, 837250, 838100, and 838250

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Body Protection

Normal work wear.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State Solid (tablet)

Color varies depending on strength

Odor None

Hq Not applicable No data available **Specific Gravity** Boiling Range/Point (°C/F) Not applicable Melting Point (°C/F) Not applicable Flash Point (PMCC) (°C/F) Not flammable No data available **Explosion Limits (%) Vapor Pressure** Not applicable No data available Density No data available Solubility in Water Vapor Density (Air = 1) Not applicable

10. STABILITY AND REACTIVITY

Stability

Stable under normal conditions.

Conditions to Avoid

Heat - high temperatures

Materials to Avoid

Strong oxidizers

Hazardous Polymerization

Will not occur.

Hazardous Decomposition Products

Oxides of carbon

11. TOXICOLOGICAL INFORMATION

See product insert and/or packaging for additional information.

Acute Toxicity

No relevant studies identified.

Specific Target Organ Systemic Toxicity (single and repeat)

Levothyroxine Sodium: Can cause adverse heart and central nervous system effects.

Serious Eye damage/Eye Irritation

No relevant studies identified.

Skin Corrosion/Irritation

No relevant studies identified.

Respiratory or Skin Sensitization

No relevant studies identified.

Carcinogenicity

Not considered carcinogenic by NTP, IARC, and OSHA.

Revision Date: October 17, 2011 Page 3 of 5



Material Safety Data Sheet SOLOXINE® (Levothyroxine Sodium) Tablets

Product Codes: 830100, 830250, 831100, 831250, 832100, 832250, 833100, 833250, 834100, 834250, 835100, 835250, 836100, 836250, 837100, 837250, 838100, and 838250

11. TOXICOLOGICAL INFORMATION

Germ Cell Mutagenicity

No relevant studies identified.

Toxicity to Reproduction

No relevant studies identified.

12. ECOLOGICAL INFORMATION

Mobility

No relevant studies identified.

Persistence/Degradability

No relevant studies identified.

Bio-accumulation

No relevant studies identified.

Ecotoxicity

No relevant studies identified.

13. DISPOSAL CONSIDERATIONS

Dispose of in accordance with all applicable local and national regulations.

14. TRANSPORT INFORMATION

Contact supplier for transport information.

15. REGULATORY INFORMATION

US REGULATIONS (Federal, State) and INTERNATIONAL CHEMICAL REGISTRATION LAWS

TSCA Listing

This product contains ingredients that are listed on or exempt from listing on the EPA Toxic Substance Control Act Chemical Substance (TSCA) Inventory.

DSL (Canadian) Listing

This product contains ingredients that are listed on the Domestic Substance List (DSL) or Non-Domestic Substance List (NDSL).

WHMIS Classification

This product is not a controlled substance under WHMIS.

This product was classified in accordance with the hazard criteria of the Canadian Controlled Products Regulations and the MSDS contains all the information required by these regulations.

MA Right To Know Law

This product contains the following chemicals on the Massachusetts Right to Know Law: Cellulose (9004-34-6)

PA Right To Know Law

This product contains the following chemicals on the Pennsylvania Hazardous Substance List: Cellulose (9004-34-6) - Corn Starch (9005-25-8)

NJ Right To Know Law

This product contains the following chemicals on the New Jersey Workplace Hazardous Substance List: Cellulose (9004-34-6)

California Proposition 65

This product contains the following materials which the State of California has found to cause cancer, birth defects or other reproductive harm: None

Revision Date: October 17, 2011 Page 4 of 5



Material Safety Data Sheet SOLOXINE® (Levothyroxine Sodium) Tablets Product Codes: 830100, 830250, 831100, 831250, 832100, 832250, 833100, 833250, 834100, 834250, 835100, 835250, 836100, 836250, 837100, 837250,

838100, and 838250

15. REGULATORY INFORMATION

SARA Title III Sect. 311/312 Categorization

None

SARA Title III Sect. 313

This product contains the following chemicals that are listed in Section 313 at or above de minimis concentrations: None

16. OTHER INFORMATION

NFPA Ratings

NFPA Code for Flammability - 0

NFPA Code for Health - 0

NFPA Code for Reactivity - 0

NFPA Code for Special Hazards - 0

HMIS Ratings

HMIS Code for Flammability - 0

HMIS Code for Health - 0

HMIS Code for Reactivity - 0

HMIS Code for Personal Protection - See Section 8

Abbreviations

ACGIH: American Conference of Governmental Industrial Hygienists

BOD: Biological Oxygen Demand

CAS#: Chemical Abstracts Service Number

FIFRA: Federal Insecticide, Fungicide and Rodenticide Act

IARC: International Agency for Research on Cancer

LC50: Lethal Concentration 50%

LD50: Lethal Dose 50%

N/A: Denotes no applicable information found or available

NTP: National Toxicology Program

OSHA: Occupational Safety and Health Administration

PEL: Permissible Exposure Limit STEL: Short Term Exposure Limit

TLV: Threshold Limit Value

TSCA: Toxic Substance Control Act

For further Information call: (800) 338-3659
Prepared By: EnviroNet LLC

SOLOXINE is a registered trademark of Virbac AH, Inc.

The information and recommendations presented in this MSDS are based on sources believed to be accurate. Virbac AH, Inc. assumes no liability for the accuracy or completeness of this information. It is the user's responsibility to determine the suitability of the **material** for their particular purposes. In particular, we make NO WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED, with respect to such information, and we assume no liability resulting from its use. Users should ensure that any use **or disposal** of the material is in accordance with applicable Federal, State, and local laws and regulations.

Revision Date: October 17, 2011 Page 5 of 5